Anish Bhatnagar - 26 Aug 2022 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role: Chief Executive Officer, Director
Signature: /s/ Anish Bhatnagar
Issuer symbol: SLNO
Transactions as of: 26 Aug 2022
Transactions value $: $0
Form type: 4
Filing time: 14 Oct 2022, 18:43:39 UTC
Previous filing: 29 Jul 2022
Next filing: 27 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SLNO	Common Stock						28,681	26 Aug 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SLNO	Employee stock option (right to buy)						5,736	26 Aug 2022	Common Stock	5,736	$535.5	Direct	F3, F4
holding	SLNO	Employee stock option (right to buy)						2,867	26 Aug 2022	Common Stock	2,867	$135	Direct	F3, F4
holding	SLNO	Employee stock option (right to buy)						1,999	26 Aug 2022	Common Stock	1,999	$349.5	Direct	F3, F4
holding	SLNO	Employee stock option (right to buy)						3,999	26 Aug 2022	Common Stock	3,999	$120.75	Direct	F3, F4
holding	SLNO	Employee stock option (right to buy)						4,015	26 Aug 2022	Common Stock	4,015	$90	Direct	F3, F4
holding	SLNO	Employee stock option (right to buy)						22,452	26 Aug 2022	Common Stock	22,452	$44.25	Direct	F3, F4
holding	SLNO	Employee stock option (right to buy)						26,666	26 Aug 2022	Common Stock	26,666	$24	Direct	F4, F5
holding	SLNO	Employee stock option (right to buy)						16,666	26 Aug 2022	Common Stock	16,666	$25.05	Direct	F5, F6
holding	SLNO	Employee stock option (right to buy)						23,332	26 Aug 2022	Common Stock	23,332	$51.15	Direct	F5, F7
holding	SLNO	Employee stock option (right to buy)						140,000	26 Aug 2022	Common Stock	140,000	$33.6	Direct	F5, F8
holding	SLNO	Employee stock option (right to buy)						40,666	26 Aug 2022	Common Stock	40,666	$5.1	Direct	F5, F9
holding	SLNO	Employee stock option (right to buy)						73,333	26 Aug 2022	Common Stock	73,333	$2.6	Direct	F5, F10

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022.
F2	Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3	The per share exercise price and number of shares subject to the option reflect the 1-for-5 reverse stock split effected October 15, 2017 and the 1-for-15 reverse stock split effected August 26, 2022.
F4	All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F5	The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022.
F6	One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of January 24, 2019 (the "Vesting Commencement Date") and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F7	One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of May 18, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F8	Twelve and one-half percent (12.5%) of the shares subject to the Option shall vest upon the date following the acceptance by the US FDA of an NDA submission for DCCR, twelve and one-half percent (12.5%) of the shares subject to the Option shall vest upon the submission by the Company to the European Medicines Agency European of an MAA for DCCR, and one forty-eighth (1/48th) of the remaining shares subject to the Option shall vest each month anniversary of January 8, 2021 (the "Vesting Commencement Date") on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F9	One forty-eighth (1/48th) of the shares subject to the Option shall vest on the first month anniversary of January 1, 2022 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F10	One fourth of the shares subject to the option shall vest on August 1, 2022 and each three-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.